A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis C

In brief

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Key facts

Study ID

NCT00546715

Run by

Bristol-Myers Squibb

People needed

95

Starts

2007-11-01

Expected to finish

2008-05-01

Last updated by the study team

2015-11-18

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Advanced Clinical Research Institute — Anaheim, California, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Parexel International Corporation — Baltimore, Maryland, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Bristol-Myers Squibb Clinical Pharmacology Unit — Hamilton, New Jersey, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• University Of Virginia Digestive Health Center Of Excellence — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.